Hipertrófiás kardiomiopátia: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SGLT2 2
• GLP-1 0
• MEK 2
• MAPK 0
• PI3K 0
• STAT3 0
• TTR 0
• AKT 0
• CTNNB1 0
• ERK 0
• IL-6 0
• KRAS 0
• mTOR 0
• NRF2 0
• PSEN1 0
• SHP2 0
• TP53 0

836 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · U24

  2/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  New England Research Institutes, Inc.· Wilmington, Egyesült Államok· 806 069 USD awarded in fiscal year 2026· until 2032. aug.

• NIH NHLBI · UG3

  1/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  Icahn School of Medicine at Mount Sinai· New York, Egyesült Államok· 946 567 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NHLBI · R01

  Discovery of modifier genes and molecular mechanisms in arrhythmogenic cardiomyopathy

  University of Tennessee Health Sci Ctr· Memphis, Egyesült Államok· 769 447 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NHLBI · R01

  Mutation-specific responses to myosin inhibitors in human iPSC models of HCM

  University of Wisconsin-Madison· Madison, Egyesült Államok· 581 307 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NHLBI · K99

  Investigating the interplay between viscoelastic and growth factor sequestering cues in iPSC-CMs

  University of California Santa Barbara· Santa Barbara, Egyesült Államok· 130 955 USD awarded in fiscal year 2026· until 2028. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spanyolország· EU contribution 1 499 625 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pushing boundaries: Innovating ultrafast ultrasound imaging to explore genotype-phenotype interplay in young hypertrophic cardiomyopathy – Real-time diagnosis and personalized management (5D ULTRAFAST-HCM)

  Chu Hopitaux de Bordeaux· Talence, Franciaország· EU contribution 1 499 425 EUR· until 2030. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Boosting predictive concepts on arrhythmogenesis resolving and unifying cardiac electrophysiology and structural remodelling at organ-level (HeartCORE)

  Consiglio Nazionale Delle Ricerche· Roma, Olaszország· EU contribution 2 646 938 EUR· until 2030. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  INnovative risk Stratification of heart faIlure throuGH explainable machine learning and compuTational modeling of Left Ventricle (INSIGHT-LV)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2027. máj.

• European Commission (Horizon Europe) · HORIZON-RIA

  Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions (SMASH-HCM)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finnország· EU contribution 8 546 366 EUR· until 2027. dec.· 9 countries

10 of 125 running projects, newest first. Listed amounts together: 69,9 M USD + 14,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Viz.ai, Inc.· Frissítve: 2026. szept. 23.

  “Sponsor company opted to shift design into single center investigator initiated study focus.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Cardiac Disease Quality of Life Study

  NCT04080492· The Cleveland Clinic· Frissítve: 2026. szept. 17.

  “Enrollment goal not met”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

  NCT07155434· UltraSight· Frissítve: 2026. márc. 9.

  “The sponsor terminated the study following an internal review of program priorities.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

  NCT06775886· Montefiore Medical Center· Frissítve: 2026. febr. 11.

  “PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Frissítve: 2025. dec. 18.

  “Clinical trials terminated early due to trial feasibility”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  OPIE in the Thin Interventricular Septum

  NCT04050579· NYU Langone Health· Frissítve: 2025. jún. 11.

  “Study was determined to be focused on Quality Assurance (QA) and Quality Improvement (QI), rather than research, based on its primary purpose and activities. Study was closed prior to enrollment.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Individualized Exercise Training in Hypertrophic Cardiomyopathy

  NCT07835854· Oregon Health and Science University· Forrás

• A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06112743· Bristol-Myers Squibb· Forrás

• Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions

  NCT07131371· Tampere University· Forrás

• Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Cytokinetics· Forrás

• A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

  NCT07004972· Bristol-Myers Squibb· Forrás

• Perfusion Abnormalities in Hypertrophic Cardiomyopathy

  NCT06599229· University of Virginia· Forrás

• A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Bristol-Myers Squibb· Forrás

• A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06253221· Bristol-Myers Squibb· Forrás

• NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Forrás

• Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

  NCT05648825· Xiang Wei· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 17
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 8
• Proteomics 6
• Metabolomics 2
• Immunohistochemistry 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 39
• Machine Learning 14
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 9

• Deep Survival Modeling With Echocardiographic Myocardial Texture Radiomics for Prediction of Major Adverse Cardiovascular Events in Hypertrophic Cardiomyopathy.

  J Cardiovasc Transl Res, 2026. okt.

• Deep Learning Models Capture Umbrella Sampling-Derived Energetic Trends: A Troponin C Case Study.

  J Chem Inf Model, 2026. aug.

• Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM.

  Circ Cardiovasc Imaging, 2026. aug.

• ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform.

  Brief Bioinform, 2026. márc.

• Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.

  Circ Cardiovasc Imaging, 2026. febr.

• Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy.

  Science, 2026. jan.

• Deep Learning-based Classification of Apical Hypertrophic Cardiomyopathy using Left Ventricular Opacification and Enhanced LV Apex Imaging.

  Curr Med Imaging, 2026. jan.

• Meta-Learning Coupled with Transfer Learning for Improved Few-Shot Classification of Cardiac MR Images.

  Annu Int Conf IEEE Eng Med Biol Soc, 2025. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.